KR102561697B1 - 세피아프테린의 다형체 및 그의 염 - Google Patents

세피아프테린의 다형체 및 그의 염 Download PDF

Info

Publication number
KR102561697B1
KR102561697B1 KR1020197015403A KR20197015403A KR102561697B1 KR 102561697 B1 KR102561697 B1 KR 102561697B1 KR 1020197015403 A KR1020197015403 A KR 1020197015403A KR 20197015403 A KR20197015403 A KR 20197015403A KR 102561697 B1 KR102561697 B1 KR 102561697B1
Authority
KR
South Korea
Prior art keywords
sepiapterin
free base
delete delete
crystalline
ray diffraction
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020197015403A
Other languages
English (en)
Korean (ko)
Other versions
KR20190086686A (ko
Inventor
다니엘 이. 레비
Original Assignee
피티씨 테라퓨틱스 엠피, 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 피티씨 테라퓨틱스 엠피, 인크. filed Critical 피티씨 테라퓨틱스 엠피, 인크.
Priority to KR1020237025450A priority Critical patent/KR102789662B1/ko
Publication of KR20190086686A publication Critical patent/KR20190086686A/ko
Application granted granted Critical
Publication of KR102561697B1 publication Critical patent/KR102561697B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D475/00—Heterocyclic compounds containing pteridine ring systems
    • C07D475/02—Heterocyclic compounds containing pteridine ring systems with an oxygen atom directly attached in position 4
    • C07D475/04—Heterocyclic compounds containing pteridine ring systems with an oxygen atom directly attached in position 4 with a nitrogen atom directly attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
KR1020197015403A 2016-11-29 2017-11-28 세피아프테린의 다형체 및 그의 염 Active KR102561697B1 (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020237025450A KR102789662B1 (ko) 2016-11-29 2017-11-28 세피아프테린의 다형체 및 그의 염

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662427686P 2016-11-29 2016-11-29
US62/427,686 2016-11-29
US201762546390P 2017-08-16 2017-08-16
US62/546,390 2017-08-16
PCT/US2017/063517 WO2018102315A1 (en) 2016-11-29 2017-11-28 Polymoprhs of sepiapterin and salts thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020237025450A Division KR102789662B1 (ko) 2016-11-29 2017-11-28 세피아프테린의 다형체 및 그의 염

Publications (2)

Publication Number Publication Date
KR20190086686A KR20190086686A (ko) 2019-07-23
KR102561697B1 true KR102561697B1 (ko) 2023-07-28

Family

ID=62241930

Family Applications (3)

Application Number Title Priority Date Filing Date
KR1020197015403A Active KR102561697B1 (ko) 2016-11-29 2017-11-28 세피아프테린의 다형체 및 그의 염
KR1020237025450A Active KR102789662B1 (ko) 2016-11-29 2017-11-28 세피아프테린의 다형체 및 그의 염
KR1020257010115A Pending KR20250051124A (ko) 2016-11-29 2017-11-28 세피아프테린의 다형체 및 그의 염

Family Applications After (2)

Application Number Title Priority Date Filing Date
KR1020237025450A Active KR102789662B1 (ko) 2016-11-29 2017-11-28 세피아프테린의 다형체 및 그의 염
KR1020257010115A Pending KR20250051124A (ko) 2016-11-29 2017-11-28 세피아프테린의 다형체 및 그의 염

Country Status (14)

Country Link
US (4) US11072614B2 (enExample)
EP (1) EP3548497A4 (enExample)
JP (3) JP7148533B2 (enExample)
KR (3) KR102561697B1 (enExample)
CN (2) CN116903624A (enExample)
AU (3) AU2017366879C1 (enExample)
BR (1) BR122021026889A8 (enExample)
CA (1) CA3043502A1 (enExample)
CO (1) CO2019006018A2 (enExample)
IL (2) IL266955B2 (enExample)
MA (1) MA46973A (enExample)
MX (3) MX386520B (enExample)
NZ (1) NZ753504A (enExample)
WO (1) WO2018102315A1 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130197000A1 (en) 2010-04-22 2013-08-01 Nihon University Drug and food/drink for preventing or improving cerebral dysfunction
WO2018102314A1 (en) 2016-11-29 2018-06-07 Censa Pharmaceuticals Inc. Polymorphic form of sepiapterin
IL266955B2 (en) 2016-11-29 2023-09-01 Ptc Therapeutics Mp Inc Polymorphs of spiafatrin and its salts
WO2019046849A1 (en) 2017-09-01 2019-03-07 Censa Pharmaceuticals Inc. PHARMACEUTICAL COMPOSITION COMPRISING SEPAPTERINE AND USES THEREOF
SMT202400430T1 (it) 2018-05-30 2024-11-15 Ptc Therapeutics Mp Inc Somministrazione di sepiapterina, senza alcun alimento, per uso in un metodo per incrementare l’esposizione plasmatica di sepiapterina
EP3801534A4 (en) 2018-05-30 2022-03-16 PTC Therapeutics MP, Inc. COMPOSITIONS AND METHODS TO INCREASE TETRAHYDROBIOPTERIN PLASMA EXPOSURE
CA3102070A1 (en) 2018-05-30 2019-12-05 Ptc Therapeutics Mp, Inc. Pharmaceutically acceptable salts of sepiapterin
ES2994060T3 (en) 2019-08-05 2025-01-16 Ptc Therapeutics Mp Inc Use of sepiapterin and metabolites thereof to treat radiation exposure
KR20220070477A (ko) * 2019-09-25 2022-05-31 피티씨 테라퓨틱스 엠피, 인크. 고페닐알라닌혈증 치료 방법
AU2021209935A1 (en) 2020-01-24 2022-08-18 Ptc Therapeutics Mp, Inc. Methods for treating Parkinson's disease with sepiapterin
JP2024506336A (ja) 2021-02-09 2024-02-13 ピーティーシー セラピューティクス エムピー，インコーポレイテッド 膠芽腫の治療方法
WO2022173823A1 (en) 2021-02-09 2022-08-18 Ptc Therapeutics Mp, Inc. Methods for treating covid-19 with sepiapterin
WO2023055923A1 (en) 2021-09-29 2023-04-06 Ptc Therapeutics, Inc. Pharmaceutical composition of sepiapterin
WO2024249602A2 (en) * 2023-05-30 2024-12-05 The Board Of Trustees Of The Leland Stanford Junior University Restless leg syndrome (rls) and periodic leg movements (plms) during sleep: biomarker and drug target
CN117205164B (zh) * 2023-09-30 2024-07-26 山东新时代药业有限公司 一种盐酸沙丙蝶呤片剂及其制备方法

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010523708A (ja) 2007-04-11 2010-07-15 バイオマリン ファーマシューティカル インコーポレイテッド テトラヒドロビオプテリンを投与する方法、関連する組成物および測定方法
JP2012207029A (ja) 2003-11-17 2012-10-25 Biomarin Pharmaceutical Inc 代謝障害の処置のための方法及び組成物
WO2013168693A1 (ja) 2012-05-07 2013-11-14 白鳥製薬株式会社 セピアプテリン及びテトラヒドロラクトイルプテリンの製造法
US20130336975A1 (en) 2010-12-01 2013-12-19 Benjamin H. Dutzar Anti-ngf compositions and use thereof

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5925323A (ja) 1982-03-03 1984-02-09 鐘淵化学工業株式会社 プテリン誘導体からなる脳内神経伝達物質の関わる疾病の治療剤
ES2177654T3 (es) 1994-08-05 2002-12-16 Suntory Ltd Remedio contra la degeneracion espinocerebelosa.
EP0854934A4 (en) 1995-08-18 2000-09-06 Donald W Landry DETECTION OF ORGANIC COMPOUNDS BY REGULATION OF ANTIBODY CATALYZED REACTIONS
US8188043B2 (en) 1999-07-28 2012-05-29 The Board Of Trustees Of The Leland Stanford Jr. University Nicotine in therapeutic angiogenesis and vasculogenesis
FR2859996B1 (fr) 2003-09-19 2006-02-03 Aventis Pharma Sa Solvat acetonique du dimethoxy docetaxel et son procede de preparation
WO2005041975A1 (en) 2003-10-31 2005-05-12 Altana Pharma Ag Use of bh4 for the treatment of respiratory diseases
JP2007536210A (ja) 2003-11-17 2007-12-13 メルック・エプロバ・アクチエンゲゼルシヤフト （６ｒ）−ｌ−エリスロ−テトラヒドロビオプテリンジヒドロクロライドの結晶形
AU2004290692A1 (en) 2003-11-17 2005-06-02 Biomarin Pharmaceutical Inc. Processes for preparing tetrahydrobiopterin, and analogs of tetrahydrobiopterin
EP2436379A1 (en) 2004-11-17 2012-04-04 BioMarin Pharmaceutical Inc. Stable tablet formulation
EP1819340A2 (en) * 2004-12-08 2007-08-22 Biomarin Pharmaceutical Inc. Methods and compositions for the treatment of pulmonary hypertension of the newborn
WO2006118322A1 (en) 2005-04-28 2006-11-09 Shiratori Pharmaceutical Co., Ltd. Method for producing hydrazone derivatives
US20080075666A1 (en) 2006-08-25 2008-03-27 Dudley Samuel C Jr Methods and compositions for treating diastolic dysfunction
NZ588379A (en) * 2008-03-10 2012-07-27 Takeda Pharmaceutical Crystal of benzimidazole compound
ES2736730T3 (es) 2008-08-12 2020-01-07 Orpha Swiss Gmbh Forma de administración farmacéutica que contiene tetrahidrobiopterina
AU2009331471B2 (en) 2008-12-23 2015-09-03 Boehringer Ingelheim International Gmbh Salt forms of organic compound
MX2012002179A (es) 2009-08-20 2012-03-16 Novartis Ag Compuestos heterociclicos de oxima.
US20130197000A1 (en) 2010-04-22 2013-08-01 Nihon University Drug and food/drink for preventing or improving cerebral dysfunction
EP2680848A4 (en) 2011-03-01 2014-11-05 Rubicon Res Private Ltd STABLE TETRAHYDROBIOPTERINE COMPOSITIONS
US9216178B2 (en) * 2011-11-02 2015-12-22 Biomarin Pharmaceutical Inc. Dry blend formulation of tetrahydrobiopterin
AU2017286544B2 (en) 2016-06-13 2022-10-20 Meharry Medical College Modulation of the nitric oxide synthase pathway for oral health
JP2019527242A (ja) 2016-07-29 2019-09-26 ディファーマ エッセ．ア． サプロプテリンジヒドロクロリドを含む医薬組成物キット
IL266955B2 (en) 2016-11-29 2023-09-01 Ptc Therapeutics Mp Inc Polymorphs of spiafatrin and its salts
WO2018102314A1 (en) 2016-11-29 2018-06-07 Censa Pharmaceuticals Inc. Polymorphic form of sepiapterin
TWI765936B (zh) 2016-11-29 2022-06-01 美商東京威力科創Ｆｓｉ股份有限公司 用以對處理腔室中之微電子基板進行處理的平移與旋轉夾頭
JOP20180040A1 (ar) 2017-04-20 2019-01-30 Gilead Sciences Inc مثبطات pd-1/pd-l1
WO2019046849A1 (en) 2017-09-01 2019-03-07 Censa Pharmaceuticals Inc. PHARMACEUTICAL COMPOSITION COMPRISING SEPAPTERINE AND USES THEREOF
CA3102070A1 (en) 2018-05-30 2019-12-05 Ptc Therapeutics Mp, Inc. Pharmaceutically acceptable salts of sepiapterin
EP3801534A4 (en) 2018-05-30 2022-03-16 PTC Therapeutics MP, Inc. COMPOSITIONS AND METHODS TO INCREASE TETRAHYDROBIOPTERIN PLASMA EXPOSURE
SMT202400430T1 (it) 2018-05-30 2024-11-15 Ptc Therapeutics Mp Inc Somministrazione di sepiapterina, senza alcun alimento, per uso in un metodo per incrementare l’esposizione plasmatica di sepiapterina
ES2994060T3 (en) 2019-08-05 2025-01-16 Ptc Therapeutics Mp Inc Use of sepiapterin and metabolites thereof to treat radiation exposure
KR20220070477A (ko) 2019-09-25 2022-05-31 피티씨 테라퓨틱스 엠피, 인크. 고페닐알라닌혈증 치료 방법

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012207029A (ja) 2003-11-17 2012-10-25 Biomarin Pharmaceutical Inc 代謝障害の処置のための方法及び組成物
JP2010523708A (ja) 2007-04-11 2010-07-15 バイオマリン ファーマシューティカル インコーポレイテッド テトラヒドロビオプテリンを投与する方法、関連する組成物および測定方法
US20130336975A1 (en) 2010-12-01 2013-12-19 Benjamin H. Dutzar Anti-ngf compositions and use thereof
WO2013168693A1 (ja) 2012-05-07 2013-11-14 白鳥製薬株式会社 セピアプテリン及びテトラヒドロラクトイルプテリンの製造法

Also Published As

Publication number Publication date
CN110248948B (zh) 2023-07-28
AU2017366879B2 (en) 2022-02-24
CN110248948A (zh) 2019-09-17
EP3548497A1 (en) 2019-10-09
MA46973A (fr) 2019-10-09
BR112019010222A2 (pt) 2019-08-27
BR112019010222A8 (pt) 2022-11-22
AU2017366879C1 (en) 2022-08-11
WO2018102315A1 (en) 2018-06-07
MX2021011676A (es) 2021-10-22
BR122021026889A2 (enExample) 2019-08-27
KR20190086686A (ko) 2019-07-23
MX2021011683A (es) 2021-10-22
WO2018102315A8 (en) 2018-09-07
CN116903624A (zh) 2023-10-20
CO2019006018A2 (es) 2019-06-19
US20250230164A1 (en) 2025-07-17
US11773097B2 (en) 2023-10-03
AU2024200344A1 (en) 2024-02-08
IL266955B2 (en) 2023-09-01
US20190308975A1 (en) 2019-10-10
IL301470A (en) 2023-05-01
AU2024200344B2 (en) 2025-11-06
JP7148533B2 (ja) 2022-10-05
EP3548497A4 (en) 2020-09-02
US20210300930A1 (en) 2021-09-30
JP2023002532A (ja) 2023-01-10
US11072614B2 (en) 2021-07-27
IL266955A (en) 2019-07-31
KR20250051124A (ko) 2025-04-16
KR20230117467A (ko) 2023-08-08
AU2022203481B2 (en) 2023-10-19
JP2024123011A (ja) 2024-09-10
AU2017366879A1 (en) 2019-05-30
JP2019535836A (ja) 2019-12-12
KR102789662B1 (ko) 2025-04-03
AU2022203481A1 (en) 2022-06-16
MX386520B (es) 2025-03-19
CA3043502A1 (en) 2018-06-07
US12269829B2 (en) 2025-04-08
IL266955B1 (en) 2023-05-01
MX2019006206A (es) 2019-08-14
US20240043426A1 (en) 2024-02-08
NZ753504A (en) 2025-10-31
BR122021026889A8 (pt) 2022-11-22

Similar Documents

Publication Publication Date Title
KR102561697B1 (ko) 세피아프테린의 다형체 및 그의 염
US12325706B2 (en) Polymorphic form of sepiapterin
BR112021013730A2 (pt) Composto de sulfiamidina amida-arilamida cíclica interna e uso do mesmo para tratamento de hepatite b
RU2270834C2 (ru) Соль лимонной кислоты терапевтического соединения и фармацевтические композиции на ее основе
NZ794827A (en) Polymorphs of sepiapterin and salts thereof
BR122025000511A2 (pt) Forma cristalina de base livre de sepiapterina, composição farmacêutica que a compreende, uso da mesma e método de preparação de uma formulação líquida
BR122025000503A2 (pt) Forma cristalina de base livre de sepiapterina, composição farmacêutica que a compreende, uso da mesma e método de preparação de uma formulação líquida
BR112019010222B1 (pt) Formas d e f cristalinas de base livre de sepiapterina, suas composições, usos e método de preparação de uma formulação líquida compreendendo as mesmas

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20190529

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20201127

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20221019

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20230426

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20230726

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20230726

End annual number: 3

Start annual number: 1

PG1601 Publication of registration